Bristol Myers (BMY) Squibb announced that the U.S. FDA granted approval for Opdivo Qvantig injection for subcutaneous use, a combination product of nivolumab co-formulated with recombinant human ...

Most recently, the Food and Drug Administration (FDA) approved treatment with the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors ...

The trial demonstrated that bi-immunotherapy with ipilimumab and nivolumab administered before ... demonstrated that intralesional daromun injections in the neoadjuvant setting significantly ...

A doctor or nurse gives the injections using a special needle free device. The SCIB1 or iSCIB+ enters the skin at high pressure and reaches the muscle. The team can tell you more about this. You have ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.